X @Bloomberg

Regulatory Action - US regulators rejected Replimune's skin cancer treatment [1] - The rejection signals a potentially stricter stance on drug approvals by the agency's new leadership [1] Company Impact - Replimune experienced a setback with the rejection of its skin cancer treatment [1]